Risk factors associated with the development of death events during the first year of follow-up after pulmonary thromboembolism

Purpose: to identify the factors associated with the development of death events during the year follow-up after hospitalization for pulmonary embolism (PE). Materials and methods: 93 patients with PE discharged to the outpatient stage of observation were studied. 45 (61,6%) patients were female with an average age of 66 years. The examination of patients at the stage of inclusion in the study consisted of standard methods of examination for this pathology. The diagnosis was confirmed by multislice computed tomography. Follow-up was 12 months. Statistical analysis was performed using the MedCalc Version 16.2.1. Results: during the one-year follow-up period 62 (66,7%) patients with PE were alive but 11 patients (11,8%) died, and no information was obtained about 20 patients. The causes of death were as follows: the development of recurrent PE – 4 (36,4%) patients, cancer – 3 patients (27,3%), stroke – 2 (18,1%), one patient (9,1%) died due to severe heart failure and one – myocardial infarction. A comparative analysis in the groups of alive patients (n = 62) and patients with a fatal events (n = 11) showed that the dead patients were older (78 (68; 81) vs. 65 (49; 75) years; p = 0,003), had a higher PESI score (119,0 (99,7; 137,2) vs. 88,0 (68,0; 108,0); p = 0,016) and were less compliant to prolonged anticoagulant therapy during the one year of observation (45,5% of patients (n = 5) vs. 82,3% ( = 51); p = 0,015). The ROC curve determined that a high risk of death during the one year after PE is associated with age over 70 years (p = 0,0001) and more than 95 points by PESI in the hospital period (p = 0,0001). Conclusion: The death events were developed in 11,8% of cases in patients with pulmonary embolism during the first year of follow-up. The death outcomes were significantly associated with elderly age, intermediate and high risk by PESI in the hospital period and low compliance to anticoagulant therapy extended during the year after pulmonary embolism.

pulmonary embolism, risk factors associated with the development of death events

1. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014 Nov 14;35(43):3033-69, 3069a-3069k. doi: 10.1093/eurheartj/ehu283.

2. Ermolaev A.A., Plavunov N.F., Spiridonova E.A., Stazhadze L.L. Pulmonary embolism: medical and demographic characteristics, pathophysiological features of the acute period, risk factors. Tromboz, Gemostaz i Reologia. 2011;2(46):25-33. (In Russ).

3. Berns S.A., Schmidt E.A., Nagirnyak O.A. Management of patients with pulmonary thromboembolism in a cardiological hospital from the perspective of current guidelines of the European Society of Cardiology. Kompleksnye Problemy Serdechno-Sosudistykh Zabolevaniy. 2015;(4):9096. https://doi.org/10.17802/2306-1278-20154-90-96. (In Russ).

4. Buryachkovskaya L.I., Lomakin N.V., Sumarokov AB, Shirokov E.A. Algorithms and scores for risk of thrombosis and hemorrhage in cardiology and neurology. Practical guide. 2018. p. 48. (In Russ).

5. Vasiltseva O.Ya., Vorozhtsova I.N., Lavrov A.G., Karpov R.S. Assessment of unfavourable prognosis factors in patients with pulmonary thromboembolism. Terapevtichesky Arkhiv. 2016;12:28-33. doi: 10.17116/terarkh2016881228-32. (In Russ).

6. Aujesky D., Roy P.M., Verschuren F. et al. Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open label, randomised, noninferiority trial. Lancet. 2011;378(9785):41–48. doi: 10.1016/S0140-6736(11)60824-6.

7. Otero R., Uresandi F., Jiménez D. et al. Home treatment in pulmonary embolism. Thromb. Res. 2010;126(1):1–5. doi: 10.1016/j.thromres.2009.09.026.

8. Zondag W., Mos I.C., Creemers Schild D. et al. Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. Thromb. Haemost. 2011;9(8):1500–1507. doi: 10.1111/j.1538-7836.2011.04388.x.

9. Agterof M.J., Schutgens R.E., Snijder R.J. et al. Out of hospital treatment of acute pulmonary embolism in patients with a low NT proBNP level. Thromb. Haemost. 2010;8(6):1235–1241. doi: 10.1111/j.1538-7836.2010.03831.x.

10. Sogaard K.K., Schmidt M., Pedersen L., HorvathPuho E., Sorensen H.T. 30-year mortality after venous thromboembolism: a population-based cohort study. Circulation. 2014;130:829–36. doi: 10.1161/CIRCULATIONAHA.114.009107.

11. Jen W.Y, Jeon Y.S. J., Kojodjojo P. et al. New Model for Risk Stratification of Patients With Acute Pulmonary Embolism. Clinical and Applied Thrombosis/Hemostasis. 2018. doi: 10.1177/1076029618808922.

12. Goldhaber S.Z., Visani L., De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353(9162):13861389.

13. Bongarzoni A., Rossi A., Tassinario G. et al. Prognosi a breve e a lungo termine dell’Embolia Polmonare acuta: dati dall’Italian Pulmonary Embolism Registry (IPER). In Comunicazione orale. 46° CONGRESSO NAZIONALE DI CARDIOLOGIA ANMCO, Milano, 4-6 giugno, 2015.

14. Tzoran I., Brenner B., Papadakis M. et al. VTE registry: what can be learned from RIETE? Rambam Maimonides Med. J. 2014. doi: 10.5041/ RMMJ.10171.

15. Verso M., Agnelli G., Ageno W. et al. Long-term death and recurrence in patients with acute venous thromboembolism: the MASTER registry. Thrombosis research. 2011;130(3):369-73. doi: 10.1016/j.thromres.2012.04.003.

16. Rodger M.A., Scarvelis D., Kahn S.R. et al. Longterm risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort. Thrombosis Research. 2016;143:152-158. doi: 10.1016/j.thromres.2016.03.028.

17. D’Agostino C., Zonzin P., Enea I. et al. ANMCO Position Paper: long-term follow-up of patients with pulmonary thromboembolism. Eur Heart J. 2017;19:D309-D332. doi: 10.1093/eurheartj/ sux030.

18. Satpanich P., Rojnuckarin P. Risk factors for venous thromboembolism (VTE) recurrences in Thai patients without cancer. Hematology. 2019;24(1):159-165. doi: 10.1080/10245332.2018.1535535.

19. Puurunen M.K. Gona P.N., Larson M.G. et al. Epidemiology of venous thromboembolism in the Framingham Heart Study Author links open overlay panel. Thrombosis Research. 2016;145:2733. doi: 10.1016/j.thromres.2016.06.033.

20. Kearon C., Spencer F.A., O’Keeffe D., D-Dimer Testing to Select Patients With a First Unprovoked Venous Thromboembolism Who Can Stop Anticoagulant Therapy: A Cohort Study. Ann Intern Med. 2015;162(1):27-34. doi: 10.7326/M14-1275.